Abstract
The design and synthesis of new N1-substituted 3-carboxy- and 3-phosphonopyrazoline and pyrazole amino acids that target the glutamate binding site of NMDA receptors are described. An analysis of the stereochemical requirements for high-affinity interaction with these receptors was performed. We identified two highly potent and selective competitive NMDA receptor antagonists, (5S,alphaR)-1 and (5S,alphaR)-4, which exhibit good in vitro neuroprotective activity and in vivo anticonvulsant activity by i.p. administration, suggesting that these molecules may have potential use as therapeutic agents.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amino Acids / chemical synthesis
-
Amino Acids / chemistry*
-
Amino Acids / therapeutic use
-
Animals
-
Anticonvulsants / chemical synthesis*
-
Anticonvulsants / chemistry
-
Anticonvulsants / therapeutic use
-
Binding Sites
-
Binding, Competitive
-
Drug Design
-
Mice
-
Molecular Conformation
-
Neuroprotective Agents / chemical synthesis*
-
Neuroprotective Agents / chemistry
-
Neuroprotective Agents / therapeutic use
-
Pyrazoles / chemistry*
-
Rats
-
Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors*
-
Receptors, N-Methyl-D-Aspartate / metabolism
-
Seizures / drug therapy
-
Stereoisomerism
Substances
-
Amino Acids
-
Anticonvulsants
-
Neuroprotective Agents
-
Pyrazoles
-
Receptors, N-Methyl-D-Aspartate